文献速递骨质疏松与钙磷/甲状旁腺

糖皮质激素性骨质疏松:新概念与临床启示

Glucocorticoid-induced osteoporosis: novel concepts and clinical implications.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-09-26

本文综述了糖皮质激素性骨质疏松的病理机制、骨折风险评估及防治策略。超生理浓度糖皮质激素直接抑制成骨细胞和骨细胞功能,短暂刺激破骨细胞,导致骨微结构损害和骨折风险增加。FRAX联合双能X线吸收测定是首选诊断步骤,可结合骨小梁评分等调整提高预测价值,并讨论成骨与抗骨吸收治疗策略。

要点

  • 糖皮质激素累积剂量高增加骨折风险,可致多发性椎体骨折和跌倒风险升高。
  • FRAX联合DXA是骨折风险评估首选,骨小梁评分等可优化预测。
  • 治疗策略包括成骨和抗骨吸收药物,用于预防和治疗糖皮质激素性骨质疏松。

核心结论

  • 糖皮质激素性骨质疏松由成骨细胞和骨细胞功能抑制、破骨细胞短暂激活及骨基质与肌肉分解代谢等多因素导致。
  • FRAX联合DXA是骨折风险评估第一步,骨小梁评分等调整可提高预测价值。
  • 成骨和抗骨吸收治疗策略可用于预防和治疗糖皮质激素性骨质疏松。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 高累积剂量外源性糖皮质激素导致骨折风险增加,脆性骨折可致活动障碍、频繁住院和生活质量下降。
  • 糖皮质激素过量损害骨微结构和骨强度,可致多发性椎体骨折,其他部位骨折风险也因跌倒风险增加而升高。
  • 糖皮质激素性骨质疏松机制包括直接抑制成骨细胞和骨细胞功能、短暂刺激破骨细胞形成和活性、对骨基质和肌肉蛋白的分解代谢效应及代谢改变。

关键数值与推荐

  • FRAX联合双能X线吸收测定是骨折风险评估的首选诊断步骤。
  • 应用骨小梁评分等特定调整可提高FRAX预测价值。

临床怎么用

  • 临床应使用FRAX联合DXA评估糖皮质激素使用者的骨折风险,必要时结合骨小梁评分调整。
  • 根据风险评估考虑成骨或抗骨吸收治疗以预防和治疗糖皮质激素性骨质疏松。

局限性

  • 摘要未报告综述的检索范围、纳入标准及证据等级等局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advances in targeted therapies, treatment with glucocorticoids remains a mainstay in the management of various immune-mediated diseases. High cumulative doses of exogenous glucocorticoids lead to a spectrum of side-effects, in particular increased fracture risk. Fragility fractures might result in immobility, frequent admission to hospitals, and loss of quality of life. Glucocorticoid excess impairs bone microarchitecture and bone strength and can cause multiple vertebral fractures. Fracture risk at other skeletal sites is also enhanced and triggered by an increased risk for falls. Glucocorticoid-induced osteoporosis results from direct suppression of osteoblast and osteocyte function, a transient stimulation of osteoclast formation and activity, catabolic effects on bone matrix and muscle protein, and metabolic alterations. Assessment of fracture risk using the Fracture Risk Assessment Tool (FRAX) with dual-energy X-ray absorptiometry represents the first diagnostic step; its predictive value can be improved by applying specific adjustments such as the trabecular bone score. This Review highlights how the bone microenvironment responds to supraphysiological glucocorticoid concentrations, and discusses the basis for skeletal fragility and fractures. We review the use and limitations of current and emerging imaging technologies and prediction tools, and discuss bone-forming and antiresorptive treatment strategies and their use to prevent and treat glucocorticoid-induced osteoporosis.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Hofbauer LC, Compston JE, Saag KG, et al. Glucocorticoid-induced osteoporosis: novel concepts and clinical implications. Lancet Diabetes Endocrinol. 2025. PMID: 41022095. doi:10.1016/S2213-8587(25)00251-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。